Publication | Open Access

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Placebo-controlled Phase 2OncologyMedicineMetastatic Colorectal CarcinomaColorectal CancerPathologyAmg 386PharmacotherapyCancer TreatmentPharmacologyRadiation Oncology